R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Company profile: IDEA Pharma

We are in the most competitive period ever for the pharmaceutical industry, characterised by incremental innovation and looming patent cliffs – and path-to-market strategy firm IDEA Pharma

Views & Analysis

Reimagining the future of healthcare

Johnson & Johnson’s global head of external innovation, William 'Bill' Hait, describes innovation as often being “an overnight success you’ve worked on for many years”.

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Gene addition – a new chapter in treating rare diseases

The scientific advancements of the past 30 years have transformed our understanding of the potential of gene therapy and how it may be used to tackle rare diseases.

R&D

Will cell and gene therapies disrupt reimbursement?

Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people with rare diseases and cancers – but they could also mean healthcare systems

Views & Analysis

Johnson & Johnson: Partnering to eliminate disease

J&J’s global head of external innovation communication on how partnerships are fuelling the company's vision for a World Without Disease.

Views & Analysis

Biotech in post-Brexit Britain: the future for the UK’s phar...

Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.

Company profile: IDEA Pharma

Reimagining the future of healthcare

Gene addition – a new chapter in treating rare diseases

Will cell and gene therapies disrupt reimbursement?

Johnson & Johnson: Partnering to eliminate disease

Biotech in post-Brexit Britain: the future for the UK’s phar...

Hims & Hers buys Australian digital health firm for $1.15bn

How to meet your physicians where they are online

Views & Analysis

Editor's Picks